Ocular Therapeutix, Inc. OCUL

Ocular Therapeutix, Inc. es una empresa biofarmacéutica centrada en la formulación, desarrollo y comercialización de terapias para enfermedades y condiciones del ojo. Su primer producto farmacéutico comercial, DEXTENZA, está desarrollado para el tratamiento de la inflamación ocular y el dolor después de cirugía oftálmica y el picor ocular asociado con la conjuntivitis alérgica. Sus activos en etapas más tempranas de desarrollo incluyen: el implante intravítreo de axitinib (OTX-TKI), que se encuentra en ensayos clínicos de Fase I para el tratamiento de la degeneración macular asociada a la edad (AMD) húmeda y la retinopatía diabética; el implante intracameral de travoprost (OTX-TIC), que se encuentra en ensayos clínicos de Fase II para el tratamiento del glaucoma de ángulo abierto primario u la hipertensión ocular; y el inserto intracanalicular de dexametasona (OTX-DED), para el tratamiento a corto plazo de los signos y síntomas del ojo seco; y el inserto intracanalicular de ciclosporina (OTX-CSI), para el tratamiento crónico del ojo seco, ambos de los cuales han completado ensayos clínicos de Fase II.

• GlobeNewswire Inc. 3 jul

  Diabetic Retinopathy Pipeline Insight 2026: Comprehensive Analysis of 50+ Companies and 55+ Drugs in Development

  A comprehensive pipeline analysis reveals over 50 companies developing 55+ drugs for diabetic retinopathy treatment. Key developments include Kodiak Sciences' Tarcocimab tedromer (Phase III anti-VEGF therapy), Vantage Biosciences' VX-01 (Phase II oral treatment), and Therini Bio's THN391 (Phase I fibrin-targeting therapy). The report covers therapeutic assessments across various development stages, routes of administration, and molecule types, highlighting emerging opportunities in retinal disease treatment.

  

• GlobeNewswire Inc. 1 jul

  Ocular Therapeutix™ to Participate in July Scientific and Investor Conferences

  Ocular Therapeutix announced its participation in multiple scientific conferences in July 2026, including the OIS Retina Innovation Summit and ASRS 44th Annual Meeting in Montreal. The company will present Phase 3 SOL-1 trial results for AXPAXLI (OTX-TKI), its investigational intravitreal axitinib hydrogel for neovascular age-related macular degeneration, along with real-world treatment utilization data. The company will also participate in the HC Wainwright 6th Annual Ophthalmology Virtual Conference on July 22, 2026.

  

• The Motley Fool 15 jun

  Ocular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026?

  The article compares two biotech companies with different risk profiles: Ocular Therapeutix, which has commercial revenue from its Dextenza product and is preparing an FDA application for Axpaxli, versus Prime Medicine, which is developing early-stage Prime Editing gene therapy technology. Despite Prime Medicine's moonshot potential, Ocular Therapeutix is recommended as the better choice for average investors in 2026 due to its more advanced development stage and clearer investment thesis, though both remain high-risk biotech plays.